NCT05998447 - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Biliary Tract Cancer

Interventions

DRUG

GEN-001

The capsules taken by mouth. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)

DRUG

Pembrolizumab

200 mg given by intravenous (IV) infusion once every 3 weeks

DRUG

mFOLFOX

mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3

Trial Locations (6)

RECRUITING

Ajou University Medical Center, Suwon

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Samsung Medical Center., Seoul

RECRUITING

Korea University Guro Hospital, Seoul